Drug intelligence / Profile preview

SYNT-115

Development stage: Preclinical
Lead developer: Syntis Bio
Administration: Oral

Overview

SYNT-115 is a preclinical biologic therapeutic candidate being developed by Syntis Bio for the treatment of obesity. The program utilizes the company's proprietary gut-restricted delivery platform, which is designed to localize the drug's activity within the small intestine while minimizing systemic absorption. By targeting a "derisked" biological pathway—referring to mechanisms already validated in metabolic disease—SYNT-115 aims to provide the efficacy of established metabolic biologics with a superior safety and tolerability profile by avoiding systemic side effects.

Beyond the preview

Go deeper on SYNT-115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYNT-115.

Explore the full profile